Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors

US11254667B2 · kind B2 · utility

Assignees

• Children's Hospital Medical Center · US
• The United States of America as Represented by the Secretary, Dept. of Health and Human Services · US

Inventors

• Daniel Starczynowski · Cincinnati, US
• Craig J. Thomas · Gaithersburg, US
• Garrett W. Rhyasen · Cincinnati, US
• Katelyn Melgar · Cincinnati, US
• Morgan MacKenzie Walker · New Haven, US
• Jian-Kang Jiang · Columbia, US

Key dates

• Filing date: Aug 16, 2017
• Grant date: Feb 22, 2022
• Expiry date: Aug 16, 2037

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer or blood disorders). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.